Floatz logo

Eprenetapopt

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Aprea TherapeuticsSmall moleculePhase 1/2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BB

Same molecule, other indications

Eprenetapopt is also rated in:

ovarian serous adenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CCC
Indicative ·
54 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →